Adial Pharmaceuticals (NASDAQ:ADIL – Get Free Report) announced its earnings results on Tuesday. The company reported ($0.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.23, Zacks reports.
Adial Pharmaceuticals Price Performance
Shares of NASDAQ ADIL opened at $0.77 on Thursday. Adial Pharmaceuticals has a 1 year low of $0.70 and a 1 year high of $3.10. The firm has a 50-day moving average of $0.90 and a 200 day moving average of $0.99.
Analyst Upgrades and Downgrades
Several brokerages have commented on ADIL. RODMAN&RENSHAW upgraded shares of Adial Pharmaceuticals to a “strong-buy” rating in a report on Thursday, November 14th. Rodman & Renshaw began coverage on Adial Pharmaceuticals in a research note on Thursday, November 14th. They issued a “buy” rating and a $8.00 target price for the company.
Adial Pharmaceuticals Company Profile
Adial Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder.
Featured Stories
- Five stocks we like better than Adial Pharmaceuticals
- The 3 Best Blue-Chip Stocks to Buy Now
- Eli Lilly Pours $27B Into U.S. Growth—What It Means for Investors
- Stock Average Calculator
- Why Now Might Be the Best Time to Buy Target Stock
- What Are the U.K. Market Holidays? How to Invest and Trade
- Why TJX Companies Belongs in Every Dividend Growth Portfolio
Receive News & Ratings for Adial Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adial Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
